DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2233515/nutanix-ntnx-reports-q2-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2233515 Feb 28, 2024 - While the top- and bottom-line numbers for Nutanix (NTNX) give a sense of how the business performed in the quarter ended January 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2233495/the-pennant-group-inc-pntg-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2233495 Feb 28, 2024 - While the top- and bottom-line numbers for The Pennant Group, Inc. (PNTG) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2233494/doubleverify-dv-q4-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2233494 Feb 28, 2024 - While the top- and bottom-line numbers for DoubleVerify (DV) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2233496/here-s-what-key-metrics-tell-us-about-jazz-jazz-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2233496 Feb 28, 2024 - The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.zacks.com/stock/news/2233497/castle-biosciences-inc-cstl-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2233497 Feb 28, 2024 - The headline numbers for Castle Biosciences, Inc. (CSTL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.zacks.com/stock/news/2233498/duolingo-inc-duol-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2233498 Feb 28, 2024 - While the top- and bottom-line numbers for Duolingo, Inc. (DUOL) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2233500/compared-to-estimates-national-storage-nsa-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2233500 Feb 28, 2024 - Although the revenue and EPS for National Storage (NSA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2233499/compared-to-estimates-natera-ntra-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2233499 Feb 28, 2024 - While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2233463/compared-to-estimates-clearwater-analytics-cwan-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2233463 Feb 28, 2024 - While the top- and bottom-line numbers for Clearwater Analytics (CWAN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2233462/sarepta-therapeutics-srpt-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2233462 Feb 28, 2024 - The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0